Molecular pathology of low malignant bladder transitional cell carcinoma: A current perspective

Histology and Histopathology

Volumn 20, Issue 1, 2005, Pages 147-153

  Wang, Haitao T ^a   Chang, J W ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Bladder cancer; Oncogene; Tumor suppressor genes; Urothelial hyperplasias; Well differentiated

Indexed keywords

FIBROBLAST GROWTH FACTOR 3;

BLADDER CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 9; COMPARATIVE GENOMIC HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GENE MAPPING; GENE MUTATION; HETEROZYGOSITY; HUMAN; METASTASIS; ONCOGENE H RAS; PHENOTYPE; REVIEW; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

CARCINOMA, TRANSITIONAL CELL; CHROMOSOMES, HUMAN, PAIR 9; HUMANS; PROTEIN-TYROSINE KINASES; RAS PROTEINS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, FIBROBLAST GROWTH FACTOR; SEQUENCE ANALYSIS, DNA; URINARY BLADDER NEOPLASMS;

EID: 11144347862     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Aboulkassim T.O., LaRue H., Lemieux P., Rousseau F. and Fradet Y. (2003). Alteration of the PATCHED locus in superficial bladder cancer. Oncogene 22, 2967-2971.
2. Billerey C., Chopin D., Aubriot-Lorton M.H., Ricol D., Gil Diez de Medina S., Van Rhijn B., Bralet M.P., Lefrere-Belda M.A., Lahaye J.B., Abbou C.C., Bonaventure J., Zafrani E.S., van der Kwast T., Thiery J.P. and Radvanyi F. (2001). Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 158, 1955.
3. Capon D.J., Chen E.Y., Levinson A.D., Seeburg P.H. and Goeddel D.V. (1983). Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue. Nature 302, 33-37.
4. Chang J.W., Tengxiang M. and Zjamg S. (1994). Chinese Journal of Urology 15, 405-408.
5. Chi S.G., Chang S.G., Lee S.J., Lee C.H., Kim J.I. and Park J.H. (1999). Elevated and biallelic expression of p73 is associated with progression of human bladder cancer. Cancer Res. 59, 2791
6. Diggle C.P., Cruickshank S., Olsburgh J.D., Pellegrin S., Smith B., Banks R.E., Selby P.J., Knowles M.A, Southgate J. and Harnden P. (2003). Identification of genes up-regulated in urothelial tumors. Am. J. Pathol. 163, 493-504.
7. Edwards J., Duncan P., Going J.J., Watters A.D, Grigor K.M. and Bartlett J.M. (2002). Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. J. Pathol. 196, 380-385.
8. Epstein J.I., Amin M.B., Reuter V.R. and Mostofi F.K. (1998). The World Health Organization/international Society of Urological Pathology Consensus Classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am. J. Surg. Pathol. 22, 1435-1448.
9. Fitzgerald J.M., Ramchurren N., Rieger K., Levesque P., Silverman M., Libertino J.A. and Summerhayes I.C. (1995). Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J. Natl. Cancer Inst. 87, 129-133.
10. Grossman H.B. (1996). Superficial bladder cancer: decreasing the risk of recurrence. Oncology (Huntingt) 10, 1617-1624; discussion 1624, 1627-1628.
11. Habuchi T., Yoshida O. and Knowles M.A. (1997). A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer: localization of the candidate region within a single 840 kb YAC. Hum. Mol. Genet. 913-919.
12. Habuchi T., Devlin J., Elder P.A. and Knowles M.A. (1999). Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 18, 2657-2661
13. Habuchi T., Takahashi T., Kakinuma H., Wang L., Tsuchiya N., Satoh S., Akao T., Sato K., Ogawa O., Knowles M.A. and Kato T. (2001). Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene 20, 531-537.
14. Hamed S., LaRue H., Hovington H., Girard J., Jeannotte L., Latulippe E. and Fradet Y. (2004). Accelerated induction of bladder cancer in patched heterozygous mutant mice. Cancer Res. 64, 1938-1942
15. Helpap B. and Köllermann J. (2000).Assessment of basal cell status and proliferative patterns in flat and papillary urothelial lesions: a contribution to the new WHO classification of urothelial tumors of the urinary bladder. Hum. Pathol. 31, 745-50.
16. Holmang S., Hedelin H., Anderstrom C., Holmberg E., Busch C. and Johansson S.L. (1999). Recurrence and progression in low grade papillary urothelial tumors. J. Urol. 162, 702.
17. Jones P.A. and Droller M.J. (1993). Pathways of development and progression in bladder cancer: new correlations between observations and molecular mechanisms. Semin. Urol. 11, 177-192.
18. Jordan A.M., Weingarten, J. and Murphy W.M. (1987). Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? Cancer 60, 2766.
19. Kimura F., Florl A.R., Seifert H.H., Louhelainen J., Maas S., Knowles M.A. and Schulz W.A. (2001). Destabilization of chromosome 9 in transitional cell carcinoma of the urinary bladder. Br. J. Cancer 85, 1887-193.
20. Kimura T., Suzuki H., Ohashi T., Asano K., Kiyota H. and Eto Y. (2001). The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 92, 2555
21. Knowles M.A. and Williamson M. (1993). Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res. 53, 133-139.
22. Knowles M.A. (2002). Histopathology 41(suppl.2), 403-423.
23. Knowles M.A., Habuchi T., Kennedy W., Cuthbert-Heavens D. (2003). Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res. 63, 7652-7656
24. Koss L.G. (1992) Bladder cancer from a perspective of 40 years. J. Cell. Biochem. Suppl. 161, 23-29.
25. McGarvey T.W., Maruta Y., Tomaszewski J.E., Linnenbach A.J. and Malkowicz S.B. (1998). PTCH gene mutations in invasive transitional cell carcinoma of the bladder. Oncogene 17, 1167-172.
26. Mostofi F.K., Sorbin L.H. amd Torloni H. (1973). Histological typing of urinary bladder tumours. Geneva: World Health Organization.
27. Murphy W.M., Takezawa K. and Maruniak N.A. (2002). Interobserver discrepancy using the 1998 world health organization/international society of urologic pathology classification of urothelial neoplasms: practical choices for patient case. J. Urol. 168, 968-972.
28. Nishiyama H., Gill J.H., Pitt E., Kennedy W. and Knowles M.A. (2001). Negative regulation of G(1)/S transition by the candidate bladder tumour suppressor gene DBCCR1 Oncogene 20, 2956-2964
29. Orlow I., LaRue H., Osman I., Lacombe L., Moore L., Rabbani F., Meyer F., Fradet Y. and Cordon-Cardo C. (1999). Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am. J. Pathol. 155, 105-113.
30. Rieger-Christ K.M., Mourtzinos A., Lee P.J., Zagha R.M., Cain J., Silverman M., Libertino J.A. and Summerhayes I.C. (2003). Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection Cancer 98, 737-744.
31. Saito S. (1992). Detection of H-ras gene point mutations in transitional cell carcinoma of human urinary bladder using polymerase chain reaction. Keio J. Med. 41, 80-86.
32. Sauter G.R. (1997). Molecular cytogenetic analysis of superficial urothelial cancer of the bladder. Verh Dtsch. Ges. Pathol. 81, 18-27
33. Schalken J.A., van Moorselaar R.J., Bringuier P.P. and Debruyne F.M. (1992). Critical review of the models to study the biologic progression of bladder cancer. Semin Surg Oncol. 8, 274-278.
34. Schapers R.F., Pauwels R.P., Wijnen J.T., Arends J.W., Thunnissen F.B., Coebergh J.W., Smeets A.W. and Bosman F.T. (1994). A simplified grading method of transitional cell carcinoma of the urinary bladder: reproducibility, clinical significance and comparison with other prognostic parameters. Br. J. Urol. 73, 625.
35. Serrano M., Lin A.W., McCurrach M.E., Beach D. and Lowe S.W. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602
36. Sibley K., Cuthbert-Heavens D. and Knowles M.A. (2001). Loss of heterozygosity at 4p-16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 20, 686.
37. Simoneau M., Aboulkassim T.O., LaRue H., Rousseau F. and Fradet Y. (1999). Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene 18, 157-163.
38. Spruck C.H. 3rd, Ohneseit P.F., Gonzalez-Zulueta M., Esrig D., Miyao N., Tsai Y.C., Lerner S.P., Schmutte C., Yang A.S. and Cote R. (1994). Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 54, 784-788.
39. Steinberg G.D., Trump D.L and Cummings K.B. (1992). Metastatic bladder cancer. Natural history, clinical course, and consideration for treatment. Urol. Clin. North. Am. 19, 735-746.
40. Theodorescu D., Cornil I., Fernandez B.J. and Kerbel R.S. (1990). overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc. Natl. Acad. Sci. USA 87, 9047-9051.
41. van Rhijn B.W., Lurkin I., Radvanyi F., Kirkels W.J., van der Kwast T.H. and Zwarthoff E.C. (2001). The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 61, 1265.
42. van Rhijn B.W., Montironi R., Zwarthoff E.C., Jobsis A.C. and van der Kwast T.H. (2002). Frequent FGFR3 mutations in urothelial papilloma. J. Pathol. 198, 245-251
43. van Rhijn B.W., Vis A.N., van der Kwast T.H., Kirkels W.J., Radvanyi F., Ooms E.C., Chopin D.K., Boeve E.R., Jobsis A.C. and Zwarthoff E.C. (2003). Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J. Clin. Oncol. 21, 1912-1921.
44. van Tilborg A.A., de Vries A. and Zwarthoff E.C. (2001). The chromosome 9q genes TGFBR1, TSC1, and ZNF189 are rarely mutated in bladder cancer. J. Pathol. 194, 76-80.
45. Webster M.K. and Donoghue D.J. (1997). FGFR activation in skeletal disorders: too much of a good thing. Trends Genet 13, 178.
46. Williamson M.P., Elder P.A., Shaw M.E., Devlin J. and Knowles M.A. (1995). p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum. Mol. Genet 4, 1569-77.
47. Xie J., Johnson R.L., Zhang X., Bare J.W., Waldman F.M., Cogen P.H., Menon A.G., Warren R.S., Chen L.C., Scott M.P. and Epstein E.H. Jr. (1997). Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res. 57, 2369-2372.
48. Yehenew M.A., Movilla N., Ischenko I. and Hayman M.J. (2003). The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Oncogene 22, 6909-6918.
49. Zhang Z.T., Pak J., Huang H.Y., Shapiro E., Sun T.T., Pellicer A. and Wu X.R. (2001). Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 20, 1973-1980.